Our Team

Dr. Patrick N. Shaklee

Dr. Patrick N. Shaklee obtained his Ph.D. in Biochemistry from the University of Illinois (USA) in 1985 under the direction of Professor H. Edward Conrad. Following postdoctoral work at the University of Wisconsin, Dr. Shaklee was Assistant Professor of Biochemistry at the University of North Texas from 1989-1992.

From 1992-1994, he was Scientist III at Glycomed Incorporated, and from 1994-2000 was Senior Research Scientist at Scientific Protein Laboratories. From 2000 thru 2008, Dr. Shaklee has been President and Director of Technical Operations at BioCascade Incorporated in Arlington, Wisconsin.

Dr. Shaklee’s career has focused on development of chemical, physical, and bioanalytical tools for glycosaminoglycan analysis, with a particular focus on heparin and the chondroitin sulfates. During graduate work, Dr. Shaklee developed chemical disaccharide analysis techniques for the chondroitin sulfates and keratan sulfate, demonstrated that low levels of 2-sulfated glucuronic acid were present in heparin, and subsequently discovered a specific glucurono-2-sulfatase present in human and avian lysosomal extracts. Later, in conjunction with James Knobloch, he showed the general utility and applicability of multi-angle laser light scattering to LMW-heparin molecular weight determinations. Finally, since 1999, Dr. Shaklee has been an active member of the WHO Working Group on Harmonized Methods for Unfractionated Heparin Potency Determination, and served from 2000-2007 on the USP Expert Committee on Blood and Blood Products.

Dr. Steffen Rosén

Dr. Steffen Rosén has a Ph.D. in biochemistry and started his career at Kabi Diagnostica 1978. He expanded the bioreagent purification and was responsible for the development of Coatest® Factor VIII, the first chromogenic FVIII kit. He became head of coagulation research and later Director R&D and VP Scientific and Medical Affairs at Chromogenix.

Under his guidance, several chromogenic kits in coagulation and fibrinioysis were developed as well as the clotting based Coatest® APC™ Resistance kit. Dr. Rosen was also the technical expert in patent matters at Chromogenix. In 2000, Dr. Rosen founded Rossix, a family owned, family operated company devoted to hemostasis research and diagnostics, which manufacturers hemostasis reagents. Today he serves as owner and operating manager of Rossix.